
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Ankylosing Spondylitis Market**

According to Intelli, the U.S. Ankylosing Spondylitis Market size was valued at USD 5,814.55 Million in 2024 and is projected to reach USD 9,323.36 Million by 2032, growing at a CAGR of 6.50% from 2025 to 2032.

****

Ankylosing Spondylitis (AS) is a debilitating, chronic inflammatory disease that predominantly targets the axial skeleton, especially the spine and sacroiliac joints. Classified as a type of seronegative spondyloarthritis, AS is characterized by persistent pain, stiffness, and progressive spinal fusion, which can lead to significant physical limitations and postural deformities over time. The hallmark symptom is chronic lower back pain that improves with exercise but not with rest, often beginning in late adolescence or early adulthood, a stage of life where such symptoms are easily overlooked or misattributed. While the precise cause of Ankylosing Spondylitis remains unclear, genetic predisposition plays a critical role in its development. One of the most well-established associations is with the HLA-B27 gene, which is found in a significant number of individuals with AS. However, the presence of this gene does not guarantee the onset of the disease, many carriers never develop symptoms, and conversely, some AS patients do not carry the gene at all. This suggests that additional factors are involved. Current research points to a combination of environmental influences, immune system dysfunction, and mechanical stress on the spine as contributing elements that may trigger or exacerbate the condition in genetically susceptible individuals.

While there is currently no cure for AS, early diagnosis and a proactive treatment approach can dramatically improve long-term outcomes. Management typically includes non-steroidal anti-inflammatory drugs (NSAIDs), biologic therapies such as TNF inhibitors or IL-17 inhibitors, physical therapy, and lifestyle modifications. The primary goals are to reduce inflammation, relieve pain, maintain spinal mobility, and prevent or delay complications. Empowering patients with knowledge, fostering multidisciplinary care, and supporting research into its complex origins are critical steps in changing the course of AS. Though the journey may be challenging, with timely intervention and perseverance, individuals with Ankylosing Spondylitis can reclaim control over their lives, preserve their independence, and continue to move forward with strength and resilience.

**U.S. Ankylosing Spondylitis Market Definition**

A close-up of hands holding a tablet and a pen

Description automatically generated**​**The U.S. Ankylosing Spondylitis market encompasses the landscape of healthcare products and services dedicated to the diagnosis, treatment, and management of Ankylosing Spondylitis within the United States. This market encompasses a broad spectrum of pharmaceutical treatments, medical technologies, and healthcare services designed to meet the diverse needs of individuals living with this chronic inflammatory condition.

**U.S. Ankylosing Spondylitis Market Overview**

The growth of the U.S. Ankylosing Spondylitis market is fueled by several key drivers. Increasing awareness and early diagnosis of the disease have led to higher patient volumes seeking effective treatment. The rising prevalence of autoimmune and inflammatory conditions, coupled with an aging population, continues to elevate demand for advanced therapeutic solutions. Significant advancements in biologic therapies, particularly TNF inhibitors and IL-17 inhibitors, have revolutionized disease management, offering improved outcomes and fueling market expansion. At the same time, ongoing research and development efforts are introducing new classes of therapies, such as Janus kinase (JAK) inhibitors, which block specific immune system signals to further control inflammation. Examples include tofacitinib and upadacitinib, which are either approved for other autoimmune conditions or are being tested for AS. The arrival of these novel treatments continues to diversify the therapeutic landscape, offering new hope for patients and fueling the dynamic expansion of the AS market. Favorable healthcare infrastructure, robust reimbursement policies, and increased healthcare spending further support market growth. Moreover, the growing focus on patient-centric care, including personalized medicine and biologic drug innovations, is creating new opportunities within the market.

**U.S. Ankylosing Spondylitis Market Segmentation**

The U.S. Ankylosing Spondylitis Market can be segmented in several ways, including by drug class, distribution channel, and end-users.

**U.S. Ankylosing Spondylitis Market, By Drug Class**

* A close-up of hands holding a tablet and a pen

  Description automatically generated**TNF Inhibitors**
* **IL-17 Inhibitors**
* **JAK Inhibitors**
* **NSAIDs**
* **Corticosteroids**

The U.S. Ankylosing Spondylitis market, segmented by drug class, is dominated by TNF inhibitors, which hold the largest market share due to their long-established efficacy. Drugs like etanercept, adalimumab, and infliximab continue to be the cornerstone of AS treatment, with significant adoption across both hospital and outpatient settings. However, IL-17 inhibitors, such as secukinumab and ixekizumab, are rapidly gaining market share, driven by their ability to target a different inflammatory pathway. The arrival of JAK inhibitors, such as tofacitinib and upadacitinib, is expanding treatment options and is anticipated to experience consistent growth in market share. Their oral administration provides a convenient alternative to injectable therapies, making them an attractive option for patients. Meanwhile, while NSAIDs and corticosteroids continue to be used for symptom relief, their market presence is steadily diminishing as biologic therapies and targeted treatments, which offer more effective disease-modifying benefits, gain prominence in managing Ankylosing Spondylitis.

**U.S. Ankylosing Spondylitis Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

The U.S. Ankylosing Spondylitis market, segmented by distribution channel, is driven by a mix of traditional and emerging platforms. Hospital pharmacies dominate the market, particularly for advanced biologic therapies, which require professional administration and oversight. Retail pharmacies continue to be a major distribution channel for oral treatments, including NSAIDs and corticosteroids, providing easy access for patients managing less severe symptoms. However, online pharmacies are witnessing significant A close-up of hands holding a tablet and a pen

Description automatically generatedgrowth, driven by the convenience of ordering medications from home and the increasing adoption of telemedicine.

**U.S. Ankylosing Spondylitis Market,** **By End-User**

* **Hospitals & Clinics**
* **Home Care**

The U.S. Ankylosing Spondylitis market, segmented by end-user, is characterized by two primary categories, hospitals & clinics and home care. Hospitals and clinics remain the dominant end-users, as they are central to the administration of biologic therapies, which require professional medical oversight. On the other hand, home care is an increasingly important segment as advancements in biologic therapies now allow for self-administration of treatments like injectable TNF inhibitors and JAK inhibitors. This shift towards home care is driven by the growing demand for convenience, reduced hospital visits, and patient autonomy.

**Key Players**

The “U.S. Ankylosing Spondylitis market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Novartis, Merck & Co., Inc., Sanofi, UCB Pharma, Roche, Gilead Sciences, Mylan Pharmaceuticals, GlaxoSmithKline, AstraZeneca, Eisai Co., Ltd., Celgene Corporation, Teva Pharmaceuticals, Biogen Inc., F. Hoffmann-La Roche AG, Medtronic, Horizon Therapeutics, Bayer AG, Hikma Pharmaceuticals among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, the FDA approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara, for treating plaque psoriasis and psoriatic arthritis. This approval broadens the available treatment options for Ankylosing Spondylitis patients as well.
* A close-up of hands holding a tablet and a pen

  Description automatically generatedIn 2024, Augurex and New Day Diagnostics teamed up to launch the SPINEstat assay, a new diagnostic tool for Ankylosing Spondylitis. This partnership focuses on improving early detection and diagnosis, helping patients receive faster treatment and better disease management.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Ankylosing Spondylitis market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Ankylosing Spondylitis market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1. **INTRODUCTION OF** **U.S. ANKYLOSING SPONDYLITIS MARKET**
   1. Overview of the market
   2. Scope of report
   3. Assumptions
2. **EXECUTIVE SUMMARY**
3. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
4. **U.S. ANKYLOSING SPONDYLITIS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. ANKYLOSING SPONDYLITIS MARKET, BY DRUG CLASS**

5.1 Overview

5.2 TNF Inhibitors

A close-up of hands holding a tablet and a pen

Description automatically generated 5.3 IL-17 Inhibitors

5.4 JAK Inhibitors

5.5 NSAIDs

5.6 Corticosteroids

**6 U.S. ANKYLOSING SPONDYLITIS MARKET, BY DISTRIBUTION CHANNEL**

6.1 Overview

6.2 Hospital Pharmacies

6.3 Retail Pharmacies

6.4 Online Pharmacies

1. **U.S. ANKYLOSING SPONDYLITIS MARKET, BY END USER**
   1. Overview
   2. Hospitals & Clinics
   3. Home Care

**8 U.S. ANKYLOSING SPONDYLITIS MARKET COMPETITIVE LANDSCAPE**

* 1. Overview
  2. Company Market Ranking
  3. Key Developments Strategies

1. **COMPANY PROFILES**

A close-up of hands holding a tablet and a pen

Description automatically generated**9.1 AbbVie Inc.**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. A close-up of hands holding a tablet and a pen

     Description automatically generated **Novartis**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Merck & Co., Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Sanofi**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **UCB Pharma**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Roche**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. A close-up of hands holding a tablet and a pen

     Description automatically generated**Gilead Sciences**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Mylan Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **GlaxoSmithKline**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Eisai Co., Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Celgene Corporation**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **Teva Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **Biogen Inc.**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  11. **F. Hoffmann-La Roche AG**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  12. **Medtronic**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  13. **Horizon Therapeutics**
      1. Overview
      2. A close-up of hands holding a tablet and a pen

         Description automatically generatedFinancial Performance
      3. Product Outlook
      4. Key developments
  14. **Bayer AG**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments
  15. **Hikma Pharmaceuticals**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research